Inventor
KO SOO S
US33 patents
⚠️ This page may combine multiple inventors who share the name “KO SOO S”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BRISTOL MYERS SQUIBB PHARMA CO
15 patentsUS6525069B1Feb 25, 2003
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB PHARMA CO52 citations95
US6949546B2Sep 27, 2005
N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB PHARMA CO18 citations92
US6759411B2Jul 6, 2004
Heterocyclic piperidines as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB PHARMA CO26 citations92
US6605623B1Aug 12, 2003
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB PHARMA CO36 citations92
US6521592B2Feb 18, 2003
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB PHARMA CO28 citations92
US6441001B1Aug 27, 2002
2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB PHARMA CO26 citations92
US6492400B1Dec 10, 2002
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB PHARMA CO15 citations84
US6780857B2Aug 24, 2004
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB PHARMA CO6 citations73
US6486180B1Nov 26, 2002
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB PHARMA CO10 citations72
US6706735B2Mar 16, 2004
2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB PHARMA CO3 citations63
US6919368B2Jul 19, 2005
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB PHARMA CO3 citations62
US6423718B1Jul 23, 2002
4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
BRISTOL MYERS SQUIBB PHARMA CO3 citations62
US6906066B2Jun 14, 2005
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB PHARMA CO3 citations61
US6875776B2Apr 5, 2005
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB PHARMA CO3 citations61
US7312222B2Dec 25, 2007
Heterocyclic piperidines as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB PHARMA CO0 citations52
BRISTOL MYERS SQUIBB CO
7 patentsUS7163937B2Jan 16, 2007
Cyclic derivatives as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB CO29 citations92
US7482335B2Jan 27, 2009
Cyclic derivatives as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB CO6 citations73
US7550486B2Jun 23, 2009
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB CO2 citations63
US7351720B2Apr 1, 2008
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB CO4 citations63
US7829571B2Nov 9, 2010
Cyclic derivatives as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB CO0 citations52
US7687508B2Mar 30, 2010
Cyclic derivatives as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB CO0 citations52
US7291744B2Nov 6, 2007
N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
BRISTOL MYERS SQUIBB CO2 citations52
DU PONT MERCK PHARMA
3 patentsUS5491152AFeb 13, 1996
Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis
DU PONT MERCK PHARMA40 citations92
US5583147ADec 10, 1996
Amides for the treatment of atherosclerosis
DU PONT MERCK PHARMA49 citations91
US5219879AJun 15, 1993
Heterocyclic steroid compounds
DU PONT MERCK PHARMA19 citations73